Promotion of metastasis-associated gene expression in survived PANC-1 cells following trichostatin A treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 10, 2015, Pages 1317-1325

  Chen, Zongjing ^a   Yang, Yunxiu ^a   Liu, Biao ^a   Wang, Benquan ^a   Sun, Meng ^a   Zhang, Ling ^a   Chen, Bicheng ^a   You, Heyi ^a   Zhou, Mengtao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; EMT; Metastasis; Notch pathway; Pancreatic cancer; Trichostatin A

Indexed keywords

CASPASE 3; GELATINASE A; MYC PROTEIN; NOTCH RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; TRICHOSTATIN A; UVOMORULIN; VIMENTIN; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; PANCREAS METASTASIS; PHASE CONTRAST MICROSCOPY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; METASTASIS; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; HYDROXAMIC ACIDS; NEOPLASM METASTASIS;

EID: 84945428606     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150520093040     Document Type: Article

References (42)

1. Wang, L.; Yang, G.H.; Lu, X.H.; Huang, Z.J.; Li, H. Pancreatic cancer mortality in China (1991-2000). World J. Gastroenterol., 2003, 9(8), 1819-1823.
2. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59(4), 225-249.
3. Egger, G.; Liang, G.; Aparicio, A.; Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004, 429 (6990), 457-463.
4. Esteller, M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene, 2002, 21 (35), 5427-5440
5. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 2002, 3(6), 415-428.
6. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 2002, 3(6), 415-428.
7. Lane, A.A.; Chabner, B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol., 2009, 27(32), 5459-5468.
8. Margueron, R.; Duong, V.; Castet, A.; Cavailles, V. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem. Pharmacol., 2004, 68(6), 1239-1246.
9. Dowdy, S.C.; Jiang, S.; Zhou, X.C.; Hou, X.; Jin, F.; Podratz, K. C.; Jiang, S.W. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Therapeut., 2006, 5(11), 2767-2776.
10. Cates, J.M.; Byrd, R.H.; Fohn, L.E.; Tatsas, A.D.; Washington, M. K.; Black, C.C. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas, 2009, 38(1), e1-6.
11. Nakajima, S.; Doi, R.; Toyoda, E.; Tsuji, S.; Wada, M.; Koizumi, M.; Tulachan, S.S.; Ito, D.; Kami, K.; Mori, T.; Kawaguchi, Y.; Fujimoto, K.; Hosotani, R.; Imamura, M. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin. Cancer Res., 2004, 10(12 Pt 1), 4125-4133.
12. Leong, K.G.; Karsan, A. Recent insights into the role of Notch signaling in tumorigenesis. Blood, 2006, 107(6), 2223-2233.
13. Hu, h.; Zhou, L.; Awadallah, A.; Xin, W. Significance of Notch1- signaling pathway in human pancreatic development and carcinogenesis. Nat. Rev. Cancer, 2013, 21(3), 242-247.
14. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A.S.; Ali, S.; Abbruzzese, J.L.; Gallick, G.E.; Sarkar, F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res., 2009, 69(6), 2400-2407.
15. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25(4), 402-408.
16. Yasui, W.; Oue, N.; Ono, S.; Mitani, Y.; Ito, R.; Nakayama, H. Histone acetylation and gastrointestinal carcinogenesis. Ann. New York Acad. Sci., 2003, 983, 220-231.
17. Ferrara, F.F.; Fazi, F.; Bianchini, A.; Padula, F.; Gelmetti, V.; Minucci, S.; Mancini, M.; Pelicci, P.G.; Lo Coco, F.; Nervi, C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 2001, 61(1), 2-7.
18. Karagiannis, T.C.; El-Osta, A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene, 2006, 25 (28), 3885-3893.
19. Pandolfi, P.P. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother. Pharmacol., 2001, 48 Suppl 1, S17-19.
20. Korsmeyer, S.J.; Shutter, J.R.; Veis, D.J.; Merry, D.E.; Oltvai, Z. N. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Sem. Cancer Biol., 1993, 4(6), 327-332.
21. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 1997, 3(8), 917-921.
22. Suzuki, A.; Ito, T.; Kawano, H.; Hayashida, M.; Hayasaki, Y.; Tsutomi, Y.; Akahane, K.; Nakano, T.; Miura, M.; Shiraki, K. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene, 2000, 19(10), 1346-1353.
23. Carrasco, R.A.; Stamm, N.B.; Marcusson, E.; Sandusky, G.; Iversen, P.; Patel, B.K. Antisense inhibition of survivin expression as a cancer therapeutic. Mol. Cancer Therapeut., 2011, 10(2), 221- 232.
24. Cosgrave, N.; Hill, A.D.; Young, L.S. Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J. Mol. Endocrinol., 2006, 37(3), 377-390.
25. Mirza, A.; McGuirk, M.; Hockenberry, T.N.; Wu, Q.; Ashar, H.; Black, S.; Wen, S.F.; Wang, L.; Kirschmeier, P.; Bishop, W.R.; Nielsen, L.L.; Pickett, C.B.; Liu, S. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 2002, 21(17), 2613-2622.
26. Gazzaniga, G.M.; Papadia, F.S.; Dezzana, M.; Cappato, S.; Filauro, M.; Bandelloni, R. Role of p53 mutations on survival after pancreatoduodenectomy for ductal adenocarcinoma of the pancreatic head. Hepato-gastroenterology, 2001, 48(42), 1743-1745.
27. Greenblatt, M.S.; Bennett, W.P.; Hollstein, M.; Harris, C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 1994, 54(18), 4855-4878.
28. Nelson, W.G.; Kastan, M.B. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 1994, 14(3), 1815-1823.
29. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell, 1997, 88(3), 323-331.
30. Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M.A.; Caldwell, M.E.; Allard, D.; Frese, K.K.; Denicola, G.; Feig, C.; Combs, C.; Winter, S.P.; Ireland-Zecchini, H.; Reichelt, S.; Howat, W.J.; Chang, A.; Dhara, M.; Wang, L.; Ruckert, F.; Grutzmann, R.; Pilarsky, C.; Izeradjene, K.; Hingorani, S. R.; Huang, P.; Davies, S. E.; Plunkett, W.; Egorin, M.; Hruban, R.H.; Whitebread, N.; McGovern, K.; Adams, J.; Iacobuzio-Donahue, C.; Griffiths, J.; Tuveson, D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 2009, 324(5933), 1457-1461.
31. Arumugam, T.; Ramachandran, V.; Fournier, V.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; MacConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res., 2009, 69(14), 5820-5828.
32. Hugo, H.; Ackland, M. L.; Blick, T.; Lawrence, M.G.; Clements, J. A.; Williams, E.D.; Thompson, E.W. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J. Cell Physiol., 2007, 213(2), 374-383.
33. Kong, D.; Li, Y.; Wang, Z.; Banerjee, S.; Ahmad, A.; Kim, H.R.; Sarkar, F.H. miR-200 regulates PDGF-D-mediated epithelialmesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells, 2009, 27(8), 1712-1721.
34. Kong, D.; Banerjee, S.; Ahmad, A.; Li, Y.; Wang, Z.; Sethi, S.; Sarkar, F.H. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoSOne, 2009, 5(8), e12445.
35. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2010, 29(34), 4741-4751.
36. Thiery, J.P.; Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol., 2006, 7(2), 131-142.
37. Lin, C.Y.; Tsai, P.H.; Kandaswami, C.C.; Lee, P.P.; Huang, C.J.; Hwang, J.J.; Lee, M.T. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. Cancer Sci., 2011, 102(4), 815-827.
38. Prince, H.; Bishton, M.; Johnstone, R. Panobinostat (LBH589): A potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol., 2009, 5(5), 601-612.
39. Grego-Bessa, J.; Diez, J.; Timmerman, L.; De la Pompa, J.L. Notch and epithelial-mesenchyme transition in development and tumor progression: Another turn of the screw. Cell cycle, 2004, 3(6), 718- 721.
40. Leong, K.G.; Niessen, K.; Kulic, I.; Raouf, A.; Eaves, C.; Pollet, I.; Karsan, A. Jagged1-mediated Notch activation induces epithelialto- mesenchymal transition through Slug-induced repression of Ecadherin. J. Exp. Med., 2007, 204(12), 2935-2948.
41. Sahlgren, C.; Gustafsson, M.V.; Jin, S.; Poellinger, L.; Lendahl, U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc. Nat. Acad. Sci. USA, 2008, 105(17), 6392-6397.
42. Dejuan, K.; Aamir, A.; Bin, B.; Yiwei, L.; Sanjeev, B.; Fazlul, H. S. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PLoSOne, 2012, 7(9), e45045.